VLA1601 Zika Vaccine March 2023
Valneva SE's VLA1601 is a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide. Valneva currently has this vaccine development program on hold. However, the Company intends to conduct a roundtable on Zika vaccines at the 23rd World Vaccine Congress in Washington, D.C., in April 2023.
France-based Valneva is a specialty vaccine company focused on preventing diseases with significant unmet needs. Valneva's vaccine portfolio includes two commercial vaccines for travelers.
VLA1601 is a vaccine candidate indicated to prevent Zika infection. First identified in Uganda in 1947 in monkeys, Zika was later identified in humans in 1952. Zika outbreaks have been reported in tropical Africa, Southeast Asia, the Pacific Islands, and the Americas. According to the World Health Organization, there is scientific consensus that ZIKV is a cause of microcephaly and Guillain-Barré syndrome.
In a phase 1 clinical trial, VLA1601 was administered intramuscularly in the deltoid muscle. Each dose is administered intramuscularly in the deltoid muscle on Days 0 and 28. Also, an accelerated 2-dose vaccination schedule on Days 0 and 7 will be assessed for both doses.
VLA1601 Vaccine News 2023
March 30, 2023 - Valneva's Chief Medical Officer, Juan Carlos Jaramillo, MD, will host a discussion on the opportunities and challenges for developing Zika vaccines on April 4, 2023.
VLA1601 Clinical Trial
Valneva has concluded the Phase 1 trial. First Posted: February 7, 2018; Last Update Posted: July 5, 2019.